The company uses proprietary screening technology and biological engineering tools to design microbial strains for efficient and cost-competitive bioproduction of chemicals and proteins. FGen's nonoliter-reactor (NLR) platform enables the screening of cell libraries at rates of more than 1 million clones per day, surpassing multi-well plate systems by orders of magnitude. The NLR technology has successfully been used for the production of small molecules and proteins by bacteria, yeast, fungi, and mammalian cells. FGen collaborates with partners from biotech, life sciences, and pharma to develop new biopharmaceuticals and establish efficient bioprocesses.